Advertisement

Cognitive Dysfunction, Mood Disorders, and Fatigue

  • Elana Farace
  • Zarui Melikyan

Summary

Changes in neurocognition, such as in memory, language, or speed of thinking, are among the most frequent complaints in cancer survivors. The degree of cognitive deficits may vary from very subtle changes in areas unimportant to the patient to very pronounced difficulties in several cognitive domains preventing the person from independent functioning or even requiring hospitalization. Neurocognitive deficits have a significant effect on patients’ quality of life (QOL) with more severe impairment leading to lower QOL. Cancer treatments such as radiation and chemotherapy have the potential to interact with neurocognition. Additionally, changes in mood and other psychiatric symptoms, and fatigue, can have significant impact on quality of life.

Key Words

quality of life neurocognition depression fatigue 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Committee on Cancer Survivorship: Improving Care and Quality of Life. Hewitt M, Greenfield S, Stovall E (eds.). From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, D.C.: National Academies Press; 2005.Google Scholar
  2. 2.
    Farace E, Shaffrey M.E. Neuropsychological issues. In: Schiff D. O’Neill BP, ed. Principles of Neuro-oncology. New York: McGraw-Hill; 2005:201–217.Google Scholar
  3. 3.
    Meyers CA, Kayl A.E. Neurocognitive function In: Levin VA, ed. Cancer in the Nervous System. 2nd ed. New York: Oxford University Press; 2002.Google Scholar
  4. 4.
    Kayl AE, Meyer CA. Neuropsychological impact of brain metastases and its treatment. In: Sawaya R, ed. Intracranial Metastases. Malden, MA: Blackwell Futura; 2004.Google Scholar
  5. 5.
    Kayl AE, Meyer CA. Neuropsychological complications in patients with brain tumors. In: Booth S. Bruera E, Oliver D, eds. Palliative Care Consultations in Primary and Metasatic Brain Tumors. Oxford: Oxford University Press; 2004.Google Scholar
  6. 6.
    Martin GN. Human Neuropsychology. Englewood Cliffs, NJ: Pearson/Prentice Hall, 2006.Google Scholar
  7. 7.
    Lezak MD. Neuropsychological Assessment. 3rd ed. New York: Oxford University Press; 1995:650–685.Google Scholar
  8. 8.
    Halligan PW, Kischka U, Marshall JC, ed. Handbook of Clinical Neuropsychology. New York: Oxford University Press; 2003.Google Scholar
  9. 9.
    Heilman KM, Valentine E, ed. Clinical Neuropsychology. 4th ed. New York: Oxford University Press; 2003.Google Scholar
  10. 10.
    Weitzner MA, Meyers CA. Quality of life and neurobehavioral functioning in patients with malignant gliomas. In: Yung WKA, ed. Ballieres Clinical Neurology: Cereberal Gliomas. London: Bailliere Tindall; 1996:425–439.Google Scholar
  11. 11.
    Meyers CA. Quality of life of brain tumor patients. In: Benstein M. BM, ed. Essential Neuro-oncology. New York: Thieme; 2000:466–472.Google Scholar
  12. 12.
    Coltheart M. The Cognitive Neuropsychology of Language. London: Erlbaum; 1987.Google Scholar
  13. 13.
    Hillis AE. The Handbook of Adult Language Disorders: Integrating Cognitive Neuropsychology, Neurology, and Rehabilitation. Philadelphia: Psychology Press; 2002.Google Scholar
  14. 14.
    Tucha O, Smely C, Preier M et al. Cognitive deficits before treatment among patients with brain tumors. Neurosurgery 2000;47:324–334.PubMedCrossRefGoogle Scholar
  15. 15.
    Packer RJ, Miller DC, Shaffrey M et al. Intracranial neoplasms. In: Rosenberg RN, Pleasure DE, ed. Comprehensive Neurology. New York: John Wiley; 1998:187–243.Google Scholar
  16. 16.
    Lilja A, Smith GJ, Salford LG. Microprocesses in perception and personality. J Nerv Ment Dis 1992;180(2):82–88.Google Scholar
  17. 17.
    Scheibel RS, Meyers CA, Levin VA. Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol 1996;30(1):61–69.PubMedCrossRefGoogle Scholar
  18. 18.
    Gottwald B, Wilde B, Mihajlovic Z et al. Evidence for distinct cognitive deficits after focal cerebellar lesions. J Neurol Neurosurg Psychiatry 2004;75(11):1524–1531.PubMedCrossRefGoogle Scholar
  19. 19.
    Renning C,. Sundet K, Due-Tonnessen B, et al. Persistent cognitive dysfunction secondary to cerebellar injury in patients treated for posterior fossa tumors in childhood. Pediatr Neurosurgery 2005;41(1):15–21.CrossRefGoogle Scholar
  20. 20.
    Schmahman JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain 1998;121:561–579.CrossRefGoogle Scholar
  21. 21.
    Riva D, Giorgi C. The cerebellum contributes to higher functions during development: evidence from a series of children surgically treated for posterior fossa tumors. Brain 2000;123:1051–1061.PubMedCrossRefGoogle Scholar
  22. 22.
    Levinsohn L, Cronin-GolombA, Schmahmann JD. Neuropsychological consequences of cerebellar tumour resection in children: cerebellar cognitive affective syndrome in a paediatric population. Brain 2000;123:1041–1050.Google Scholar
  23. 23.
    Molinari M, Leggio MG, Silveri MC. Verbal fluency and agrammatism. In: Schmahmann JD ed. The Cerebellum and Cognition: International Review of Neurobiology. San Diego: Academic Press; 1997:325–339.Google Scholar
  24. 24.
    Leggio MG, Silveri MC, Petrosini L, et al. Phonological grouping is specifically affected in cerebellar patients: a verbal fluency study. J Neurol Neurosurg Psychiatry 2000;69:102–106.PubMedCrossRefGoogle Scholar
  25. 25.
    Fiez JA, Petersen SE, Cheney MK, et al. Impaired nonmotor learning and error detection associated with cerebellar damage. Brain 1992;115:155–178.PubMedCrossRefGoogle Scholar
  26. 26.
    Grafman J, Litvan I, Massaquoi S et al. Cognitive planning deficit in patients with cerebellar atrophy. Neurology 1992;42:1493–1496.PubMedGoogle Scholar
  27. 27.
    Appollonio IM Grafman J, Schwartz V et al. Memory in patients with cerebellar degeneration. Neurology 1993;43:1536–1544.Google Scholar
  28. 28.
    Drepper J, Timmann D, Kolb FP et al. Nonmotor associative learning in patients with isolated degenerative cerebellar disease. Brain 1999;122:87–97.PubMedCrossRefGoogle Scholar
  29. 29.
    Townsend J, Courchesne E, Covington J et al. Spatial attention deficits in patients with acquired or developmental cerebellar abnormality. J Neurosci 1999;19:5632–5643.PubMedGoogle Scholar
  30. 30.
    Courchesne E, Townsend J, Akshoomoff NA et al. Impairment in shifting attention in autistic and cerebellar patients. Behavioral Neurosci 1994;108:848–865.Google Scholar
  31. 31.
    Gomez Beldarrain M, Garcia-Monco JC, Quintana JM et al. Diaschisis and neuropsychological performance after cerebellar stroke. Eur Neurol 1997;37:82–89.PubMedCrossRefGoogle Scholar
  32. 32.
    Helmuth LL, Ivry RB, Shimizu N. Preserved performance by cerebellar patients on tests of word generation, discrimination learning, and attention. Learning and Memory 1997;3:456–474.PubMedCrossRefGoogle Scholar
  33. 33.
    Daum I. AH. Neuropsychological abnormalities in cerebellar syndromes: fact or fiction? In: Schmahmann J.D, ed. The Cerebellum and Cognition. International Review of Neurobiology. San Diego: Academic Press; 1997:61–83.Google Scholar
  34. 34.
    Friedman MA, Meyers CA, Sawaya R. Neuropsychological effects of third ventricle tumor surgery. Neurosurgery 2003;52(4):791–798; discussion 8.PubMedCrossRefGoogle Scholar
  35. 35.
    Kayl AE MC. Does brain tumor histology influence cognitive function? Neuro-oncol 2003(5):255–260.Google Scholar
  36. 36.
    Klein M, Houx PJ, Jolles J. Long-term persisting cognitive sequeale traumatic brain injury and the effect of age. J Neuropathol Mental Disorders 1996;184:459–467.Google Scholar
  37. 37.
    Nussbaun ES, Djalilian HR, Cho KH et al. Brain metastases: histology, multiplicity, surgery and survival. Cancer 1996;78(8):1781–1788.Google Scholar
  38. 38.
    Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin 2003;21(1):1–23, vii.PubMedCrossRefGoogle Scholar
  39. 39.
    Farace E, Shaffrey M.E. Neuropsychological issues. In: Schiff D. O’Neill BP, ed. Principles of Neuro-oncology. New York: McGraw–Hill; 2005.Google Scholar
  40. 40.
    Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro-oncol 2003;5(2):89–95.PubMedCrossRefGoogle Scholar
  41. 41.
    Fox SW, Lyon D, Farace E. Symptom clusters in patients with high-grade glioma. J Nurs Scholarsh 2007;39(1):61–67.PubMedCrossRefGoogle Scholar
  42. 42.
    Mainio A, Tuunanen S, Hakko H et al. Decreased quality of life and depression as predictors for shorter survival among patients with low-grade gliomas: a follow-up from 1990 to 2003. Eur Arch Psychiatry Clin Neurosci 2006;256(8):516–521.Google Scholar
  43. 43.
    Klein M, Heimans JJ, Aaronson NK et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361–1368.Google Scholar
  44. 44.
    Meyers CA, Hess KR, Yung WKA et al. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clini Oncol 2000;18(3):646.Google Scholar
  45. 45.
    Herman MA, Tremont-Lukats I, Meyers CA et al. Neurocognitive and functional assessment of patients with brain metastases: a pilot study. Am J Clin Oncol 2003;26(3):273–279.PubMedCrossRefGoogle Scholar
  46. 46.
    Laws ER. The decade of the brain: 1990–2000. Neurosurgery 2000;47(6):1257–1260.Google Scholar
  47. 47.
    Laws E, Shaffrey M. Surgical management of intracranial gliomas: biopsy resection or watchful waiting. Clin Neurosurg 2001;48:37–45.Google Scholar
  48. 48.
    Peyser JM, Rao SM, LaRocca NG et al. Guidelines for neuropsychological research in multiple sclerosis. Arch Neurol 1990;47(1):94–97.PubMedGoogle Scholar
  49. 49.
    Jelic V, Johansson SE, Almkvist O et al. Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer’s disease. Neurobiol Aging 2000;21(4):533–540.Google Scholar
  50. 50.
    Arfken CL, Lichtenberg PA, Tancer ME. Cognitive impairment and depression predict mortality in medically ill older adults. J Gerontol Ser A Biol Sci Med Sci 1999;54(3):M152–M156.Google Scholar
  51. 51.
    Pahlson A, Ek L, Ahlstrom G, Smits A. Pitfalls in the assessment of disability in individuals with low-grade gliomas. J Neuro-Oncol 2003;65(2):149–158.Google Scholar
  52. 52.
    Farace E., Sheehan J. M. Majority of brain tumor patients show neurocognitive improvement after initial surgical resection In: Society of Neurooncology 12th Meeting; 2007; Dallas, TX; 2007.Google Scholar
  53. 53.
    Teixidor P, Gatignol P, Leroy M et al. Assessment of verbal working memory before and after surgery for low-grade glioma. J Neurooncol 2007;81(3):305–313.Google Scholar
  54. 54.
    Duffau H, Capelle L, Denvil D, et al. Functional recovery after surgical resection of low-grade gliomas in eloquent brain: hypothesis of brain compensation. J Neurol Neurosurg Psychiatry 2003;74(7):901–907.Google Scholar
  55. 55.
    Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322(8):494–500.PubMedGoogle Scholar
  56. 56.
    Vecht CJ, Haaxma-Reiche H, Noordijk EM et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993;33(6):583–590.PubMedCrossRefGoogle Scholar
  57. 57.
    Mintz AH, Kestle J, Rathbone MP et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996;78(7):1470–14776.PubMedCrossRefGoogle Scholar
  58. 58.
    Bindal RK, Sawaya R, Leavens ME et al. Surgical treatment of multiple brain metastases. J Neurosurg 1993;79(2):210–216.PubMedGoogle Scholar
  59. 59.
    Walker MD, Alexander E, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 1978;49:333–343.PubMedGoogle Scholar
  60. 60.
    Kristiansen K, Hagen S, Kollevold T et al. Combined modality therapy of operated astrocytomas grade III and IV: confirmation of the value of post-operative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649–652.Google Scholar
  61. 61.
    Stupp R, Mason W, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–996.Google Scholar
  62. 62.
    Sneed PK, Suh JH, Goetsch SJ et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Rad Oncol Biol Phys 2002;53:519–526.Google Scholar
  63. 63.
    Crossen JR Garwood D, Glatstein E et al. Neurobehavioral sequale of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994;12:627–642.Google Scholar
  64. 64.
    Surma-aho O, Niemela M, Vilkki J et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 2001;56(10):1285–1290.Google Scholar
  65. 65.
    DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology 1989;56:1285–1290.Google Scholar
  66. 66.
    Lee AW, Kwong DL, Leung SW et al. Factors affecting risk of symptomatic temporal lobe necrosis: significant of fractional dose and treatment time. Int J Rad Oncol Biol Phys 2002(53):75–85.Google Scholar
  67. 67.
    Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007;25(10):1260–1266.Google Scholar
  68. 68.
    Meyers CA, Smith JA, Bezjak A et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004;22(1):157–165.PubMedCrossRefGoogle Scholar
  69. 69.
    Nordal RA, Nagy A, Pintilie M et al. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res 2004;10(10):3342–3353.PubMedCrossRefGoogle Scholar
  70. 70.
    Abayomi OK. Pathogenesis of cognitive decline following therapeutic irradiation for head and neck tumors. Acta Oncol 2002;41(4):346–351.Google Scholar
  71. 71.
    Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol 2004;3(3):159–168.PubMedCrossRefGoogle Scholar
  72. 72.
    Nordal RA, Wong CS. Intercellular adhesion molecule-1 and blood–spinal cord barrier disruption in central nervous system radiation injury. J Neuropathol Exp Neurol 2004;63(5):474–483.PubMedGoogle Scholar
  73. 73.
    Fujii O, Tsujino K, Soejima T et al. White matter changes on magnetic resonance imaging following whole-brain radiotherapy for brain metastases. Radiat Med 2006;24(5):345–350.Google Scholar
  74. 74.
    Sarkissian V. The sequelae of cranial irradiation on human cognition. Neurosci Lett 2005;382(1–2):118–123.Google Scholar
  75. 75.
    Armstrong CL, Gyato K, Awadalla AW et al. A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversy. Neuropsychol Rev 2004;14(1):65–86.PubMedCrossRefGoogle Scholar
  76. 76.
    Eriksson PS, Perfilieva E, Bjork–Eriksson T et al. Neurogenesis in the adult human hippocampus. Nat Med 1998;4(11):1313–1317.PubMedCrossRefGoogle Scholar
  77. 77.
    Monje ML, Palmer T. Radiation injury and neurogenesis. Curr Opin Neurol 2003;16(2):129–134.PubMedCrossRefGoogle Scholar
  78. 78.
    Tsuruda JS, Kortman KE, Bradley WG et al. Radiation effects on cerebral white matter: MR evaluation. AJR Am J Roentgenol 1987;149(1):165–171.PubMedGoogle Scholar
  79. 79.
    Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer 2004;90(9):1691–1696.PubMedGoogle Scholar
  80. 80.
    Hochberg FH, Slotnick B. Neuropsychologic impairment in astrocytoma survivors. Neurology 1980;30(2):172–177.PubMedGoogle Scholar
  81. 81.
    Taphoorn MJ, Heimans JJ, Snoek FJ et al. Assessment of quality of life in patients treated for low-grade glioma: a preliminary report. J Neurol Neurosurg Psychiatry 1992;55(5):372–376.PubMedCrossRefGoogle Scholar
  82. 82.
    Grant R, Slattery J, Gregor A, Whittle IR. Recording neurological impairment in clinical trials of glioma. J Neurooncol 1994;19(1):37–49.Google Scholar
  83. 83.
    DeAngelis LM, Mandell LR, Thaler HT et al. The role of post-operative radiotherapy after resection of single brain metastases. Neurosurgery 1989;24(6):798–805.Google Scholar
  84. 84.
    Moretti R, Torre P, Antonello RM et al. Neuropsychological evaluation of late-onset post-radiotherapy encephalopathy: a comparison with vascular dementia. J Neurol Sci 2005;229–230:195–200.Google Scholar
  85. 85.
    Costello A, Shallice T, Gullan R et al. The early effects of radiotherapy on intellectual and cognitive functioning in patients with frontal brain tumours: the use of a new neuropsychological methodology. J Neurooncol 2004;67(3):351–359.Google Scholar
  86. 86.
    Surma-aho O, Niemela M, Vilkki J et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 2001;56(10):1285–1290.Google Scholar
  87. 87.
    Armstrong CL, Corn BW, Ruffer JE et al. Radiotherapeutic effects on brain function: double dissociation of memory systems. Neuropsychiatry Neuropsychol Behav Neurol 2000;13(2):101–111.PubMedGoogle Scholar
  88. 88.
    Laack NN, Brown PD, Ivnik RJ et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 2005;63(4):1175–1183.PubMedGoogle Scholar
  89. 89.
    Noad R, Narayanan KR, Howlett T et al. Evaluation of the effect of radiotherapy for pituitary tumours on cognitive function and quality of life. Clin Oncol (R Coll Radiol) 2004;16(4):233–237.Google Scholar
  90. 90.
    Andrews DW, Scott CB, Sperduto PW et al. Whole-brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363(9422):1665–1672.PubMedCrossRefGoogle Scholar
  91. 91.
    Sneed PK, Lamborn KR, Forstner JM et al. Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 1999;43(3):549–558.Google Scholar
  92. 92.
    Patchell RA, Regine WF. The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. Technol Cancer Res Treat 2003;2(2):111–115.PubMedGoogle Scholar
  93. 93.
    Regine WF, Huhn JL, Patchell RA et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int J Radiat Oncol Biol Phys 2002;52(2):333–338.PubMedGoogle Scholar
  94. 94.
    Regine WF, Scott C, Murray K et al. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91–04. Int J Radiat Oncol Biol Phys 2001;51(3):711–717.PubMedGoogle Scholar
  95. 95.
    Lo SS, Chang EL, Suh JH. Stereotactic radiosurgery with and without whole-brain radiotherapy for newly diagnosed brain metastases. Expert Rev Neurother 2005;5(4):487–495.PubMedCrossRefGoogle Scholar
  96. 96.
    Andrews DW, Scott C, Sperduto PW et al. Phase III randomized trial comparing whole-brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: eesults of the RTOG 9508 trial. Lancet 2004;363:1665–1673.PubMedCrossRefGoogle Scholar
  97. 97.
    Aoyama H, Shirato H, Nakagawa K et al. Interim report of the JRSOG99–1 multi-institutional randomized trial, comparing radiosurgery alone vs. radiosurgery plus whole brain irradiation for 1–4 brain metastases. Proc Amer Soc Clin Oncol 2004;23:108.Google Scholar
  98. 98.
    Chang EL, Wefel JS, Maor MH et al. A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 2007;60(2):277–283; discussion 83–84.PubMedCrossRefGoogle Scholar
  99. 99.
    Penitzka S, Steinvorth S, Sehlleier S et al. Assessment of cognitive function after preventive and therapeutic whole-brain irradiation using neuropsychological testing. Strahlenther Onkol 2002;178(5):252–258.Google Scholar
  100. 100.
    Komaki R, Meyers CA, Shin DM et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 1995;33(1):179–182.Google Scholar
  101. 101.
    Parageorgiou C, Dardoufas C, Kouloulias V et al. Psychophysiological evaluation of short-term neurotoxicity after prophylactic brain irradiation in patients with small cell lung cancer: a study of event related potentials. J Neurooncol 2000;50(3):275–285.Google Scholar
  102. 102.
    Wefel JS, Lenzi R, Theriault RL et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004;100(11):2292–2299.PubMedCrossRefGoogle Scholar
  103. 103.
    Hurria A, Rosen C, Hudis C et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc 2006;54(6):925–931.Google Scholar
  104. 104.
    Fliessbach K, Helmstaedter C, Urbach H et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 2005;64(7):1184–1188.Google Scholar
  105. 105.
    Correa DD, Deangelis LM, Shi W et al. Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol 2007;81(2):175–184.PubMedCrossRefGoogle Scholar
  106. 106.
    O’Neill BP. Neurocognitive outcomes in primary CNS lymphoma (PCNSL). Neurology 2004;62(4):532–533.Google Scholar
  107. 107.
    Correa DD, DeAngelis LM, Shi W et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004;62(4):548–555.PubMedGoogle Scholar
  108. 108.
    Harder H, Holtel H, Bromberg JE et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004;62(4):544–547.Google Scholar
  109. 109.
    Butler JM, Rapp SR, Shaw EG. Managing the cognitive effects of brain tumor radiation therapy. Curr Treat Options Oncol 2006;7(6):517–523.PubMedCrossRefGoogle Scholar
  110. 110.
    Byrne TN. Cognitive sequelae of brain tumor treatment. Curr Opin Neurol 2005;18(6):662–666.Google Scholar
  111. 111.
    Torres IJ, Mundt AJ, Sweeney PJ et al. A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology 2003;60(7):1113–1118.PubMedGoogle Scholar
  112. 112.
    Taylor BV, Buckner JC, Cascino TL et al. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma, J Clin Oncol 1998;16(6):2195–2201.Google Scholar
  113. 113.
    Brown PD, Jensen AW, Felten SJ et al. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol 2006;24(34):5427–5433.PubMedCrossRefGoogle Scholar
  114. 114.
    Frytak S, Shaw JN, O’Neill BP et al. Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol 1989;12(1):27–33.Google Scholar
  115. 115.
    Dimberg Y, Vazquez M, Soderstrom S et al. Effects of X-irradiation on nerve growth factor in the developing mouse brain. Toxicol Lett 1997;90(1):35–43.Google Scholar
  116. 116.
    Shaw EG, Rosdhal R, D’Agostino RB, Jr. et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 2006;24(9):1415–1420.Google Scholar
  117. 117.
    Prommer E. Modafinil: is it ready for prime time? J Opioid Manag 2006;2(3):130–136.Google Scholar
  118. 118.
    Meyers CA, Weitzner MA, Valentine AD et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998;16(7):2522–2527.PubMedGoogle Scholar
  119. 119.
    Cohen N, Strauss G, Lew R et al. Should prophylactic anticonvulsants be administered to patients with newly diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988(6):1621–1624.Google Scholar
  120. 120.
    Forsyth PA, Weaver S, Fulton D et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003;30(2):106–112.PubMedGoogle Scholar
  121. 121.
    Madhusoodanan S, Danan D, Moise D. Psychiatric manifestations of brain tumors: diagnostic implications. Expert Rev Neurother 2007;7(4):343–349.Google Scholar
  122. 122.
    Kelly C, Paleri V, Downs C et al. Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer. Otolaryngol Head Neck Surg 2007;136(1):108–111.Google Scholar
  123. 123.
    Gupta RK, Kumar R. Benign brain tumors and psychiatric morbidity: a 5-year retrospective data analysis. Austral New Zealand J Psychiatry 2004;38(5):316–319.CrossRefGoogle Scholar
  124. 124.
    Moise D, Madhusoodanan S. Psychiatric symptoms associated with brain tumors: a clinical enigma. CNS Spectr 2006;11(1):28–31.Google Scholar
  125. 125.
    Cummings JL. Dementia: A Clinical Approach. Stoneham, MA: Butterworth-Heinemann; 1992.Google Scholar
  126. 126.
    Scharre. Neoplastic, demyelinating, infectious, and inflammatory brain disorders. In: Coffey CE CJ, ed. Textbook of Geriatric Neuropsychiatry. Washington, D.C.: American Psychiatric Publishing; 2000.Google Scholar
  127. 127.
    Belyi BI. Mental impairment in unilateral frontal tumours: role of the laterality of the lesion. Int J Neurosci 1987;32(3–4):799–810.Google Scholar
  128. 128.
    Price T, Lovell MR. Neuropsychiatric aspects of brain tumors. In: Yudofsky SC, Hales RE, ed. Neuropsychiatry and Clinical Neurosciences. Washington, D.C.: American Psychiatric Publishing; 2002.Google Scholar
  129. 129.
    Nasrallah HA, McChesney CM. Psychopathology of corpus callosum tumors. Biol Psychiatry 1981;16(7):663–669.PubMedGoogle Scholar
  130. 130.
    Schmahmann JD. Disorders of the cerebellum: ataxia, dysmetria of thought and the cerebellar cognitive affective syndrome. J Neuropsychiatry Clin Neurosci 2004(16):367–378.Google Scholar
  131. 131.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, D.C.; 1994.Google Scholar
  132. 132.
    Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology (Huntington) 2000;14(1):75–79. %%AQ[21]Ref 133 cited in %%text but not listed in ref list. Please check %%setcounterenumiv133Google Scholar
  133. 133.
    Endicott J. Measurement of depression in patients with cancer. Cancer 1984;53:2243–2248.Google Scholar
  134. 134.
    Valentine AD, Meyers CA. Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients. Cancer 2001;92(6):1694–1698.PubMedCrossRefGoogle Scholar
  135. 135.
    Mainio A, Hakko H, Niemela A et al. Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry 2006;21(3):194–199.Google Scholar
  136. 136.
    Massie MJ. Depressive disorders. In: Holland JC, ed. Psycho-oncology. New York: Oxford University Press; 1998:518–540.Google Scholar
  137. 137.
    Derogatis LR, Morrow GR, Fetting J. The prevalence of psychiatric disorders among cancer patients. JAMA 1983(249):751–757.Google Scholar
  138. 138.
    Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosomatic Medicine 1984(46):199–212.Google Scholar
  139. 139.
    Pirl WF, Roth AJ. Diagnosis and treatment of depression in cancer patients. Oncology (Huntington) 1999(13):1293–1306.Google Scholar
  140. 140.
    Pringle AM, Taylor R, Whittle IR. Anxiety and depression in patients with an intracranial neoplasm before and after tumour surgery. Br J Neurosurg 1999;13(1):46–51.PubMedCrossRefGoogle Scholar
  141. 141.
    Weitzner MA, Kanfer S, Booth–Jones M. Apathy and pituitary disease: it has nothing to do with depression. J Neuropsychiatry Clin Neurosci 2005;17(2):159–166.PubMedGoogle Scholar
  142. 142.
    Edvardsson T, Pahlson A, Ahlstrom G. Experiences of onset and diagnosis of low-grade glioma from the patient’s perspective. Cancer Nurs 2006;29(5):415–422.Google Scholar
  143. 143.
    Mainio A, Hakko H, Niemela A et al. Depression and functional outcome in patients with brain tumors: a population-based 1-year follow-up study. J Neurosurg 2005;103(5):841–847.Google Scholar
  144. 144.
    Litofsky NS, Farace E, Anderson F, Jr. et al. Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 2004;54(2):358–366.PubMedCrossRefGoogle Scholar
  145. 145.
    Mantani T, Saeki T, Inoue S et al. Factors related to anxiety and depression in women with breast cancer and their husbands: role of alexithymia and family functioning. Support Care Cancer 2007(10).Google Scholar
  146. 146.
    Hauser P, Soler R, Reed S et al. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000;41(5):439–441.Google Scholar
  147. 147.
    Scheibel RS, Valentine AD, O’Brien S et al. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci 2004;16(2):185–191.PubMedGoogle Scholar
  148. 148.
    Badger CT, Dorros SM, Meek P et al Depression and anxiety in women with breast cancer and their partners. Nursing Research 2007;56(1):44–53.PubMedCrossRefGoogle Scholar
  149. 149.
    Campbell LC, Keefe FJ, Scipio C et al. Facilitating research participation and improving quality of life for African-American prostate cancer survivors and their intimate partners : a pilot study of telephone-based coping skills training. Cancer 2007;109(15):414–424.PubMedCrossRefGoogle Scholar
  150. 150.
    Pelletier G, Verhoef MJ, Khatri N et al. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neuro-oncol 2002;57(1):41–49.Google Scholar
  151. 151.
    Osoba D, Aaronson NK, Muller M et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 1997;34(3):263–278.Google Scholar
  152. 152.
    Osoba D, Brada M, Prados MD et al. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro-oncol 2000;2(4):221–228.Google Scholar
  153. 153.
    Dimeo F, Stieglitz RD, Novelli-Fischer U et al. Correlation between physical performance and fatigue in cancer patients. Ann Oncol 1997(8):1251–1255.Google Scholar
  154. 154.
    Valentine AD, Meyers CA. Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients. Cancer 2001(92):1694–1698.Google Scholar
  155. 155.
    Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and management. Oncologist 1999;4(1):1–10.PubMedGoogle Scholar
  156. 156.
    Lai YH, Chang JT, Keefe FJ et al. Symptom distress, catastrophic thinking, and hope in nasopharyngeal carcinoma patients. Cancer Nurs 2003;26(6):485–493.PubMedCrossRefGoogle Scholar
  157. 157.
    Berger AM, Higginbotham P. Correlates of fatigue during and following adjuvant breast cancer chemotherapy: a pilot study. Oncol Nurs Forum 2000;27(9):1443–1448.PubMedGoogle Scholar
  158. 158.
    Irvine DM, Vincent L, Graydon JE et al. Fatigue in women with breast cancer receiving radiation therapy. Cancer Nurs 1998;21(2):127–135.Google Scholar
  159. 159.
    Okuyama T, Tanaka K, Akechi T et al. Fatigue in ambulatory patients with advanced lung cancer: prevalence, correlated factors, and screening. J Pain Symptom Manage 2001;22(1):554–564.Google Scholar
  160. 160.
    Blesch KS, Paice JA, Wickham R et al. Correlates of fatigue in people with breast or lung cancer. Oncol Nurs Forum 1991;18(1):81–87.PubMedGoogle Scholar
  161. 161.
    Miaskowski C, Lee KA. Pain, fatigue, and sleep disturbances in oncology outpatients receiving radiation therapy for bone metastasis: a pilot study. J Pain Symptom Manage 1999;17(5):320–332.Google Scholar
  162. 162.
    Jacobsen PB, Hann DM, Azzarello LM et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 1999;18(4):233–242.PubMedCrossRefGoogle Scholar
  163. 163.
    Yellen SB, Cella DF, Webster K et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13(2):63–74.PubMedCrossRefGoogle Scholar
  164. 164.
    Wang XS GS, Mendoza TR et al. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin’s lymphoma. J Clin Oncol 2000(20):1319–1328.Google Scholar
  165. 165.
    Wang XS JN, Johnson BA et al. Fatigue during preoperative chemoradiation for respectable rectal cancer. Cancer 2001;92:1725–1732.Google Scholar
  166. 166.
    Hwang SS, Chang VT, Rue M et al. Multidimensional independent predictors of cancer-related fatigue. J Pain Symptom Manage 2003;26(1):604–614.PubMedCrossRefGoogle Scholar
  167. 167.
    Broeckel JA, Jacobsen PB, Horton J et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 1998;16(5):1689–1696.PubMedGoogle Scholar
  168. 168.
    Visser MR, Smets EM. Fatigue, depression, and quality of life in cancer patients: how are they related? Support Care Cancer 1998;6(2):101–108.PubMedCrossRefGoogle Scholar
  169. 169.
    Van Zandvoort MJ, Kappelle LJ, Algra A et al. Decreased capacity for mental effort after single supratentorial lacunar infarct may affect performance in everyday life. J Neurol Neurosurg Psychiatry 1998;65(5):697–702.PubMedGoogle Scholar
  170. 170.
    Lovely MP, Miaskowski C, Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiformae. Oncol Nurs Forum 1999;26(5):921–925.PubMedGoogle Scholar
  171. 171.
    Groenvold M, Petersen MA, Idler E et al. Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Research and Treatment 2007 (3).Google Scholar
  172. 172.
    Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatry Clinics North America 1996(19):515–547.Google Scholar
  173. 173.
    Bruera E, Miller MJ, Macmillan K et al. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992;48(2):163–166.Google Scholar

Copyright information

© Humana Press, Totowa, NJ 2008

Authors and Affiliations

  • Elana Farace
  • Zarui Melikyan

There are no affiliations available

Personalised recommendations